NCT02647086 - Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Atopic Dermatitis

Interventions

DRUG

Dupilumab

DRUG

Midazolam

Cytochrome P450 substrate

DRUG

Omeprazole

Cytochrome P450 substrate

DRUG

Warfarin

Cytochrome P450 substrate

DRUG

Caffeine

Cytochrome P450 substrate

DRUG

Metoprolol

Cytochrome P450 substrate

Trial Locations (5)

Regeneron Study Site, Little Rock

Regeneron Study Site, Centennial

Regeneron Study Site, Minneapolis

Regeneron Study Site, Berlin

Regeneron Study Site, Raleigh